Core Laboratories (NYSE:CLB) Releases Q1 2025 Earnings Guidance

Core Laboratories (NYSE:CLB) issued an update on its first quarter 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.120-0.160 for the period, compared to the consensus EPS estimate of 0.210. The company issued revenue guidance of $121.0 million-$127.0 million, compared to the consensus revenue estimate of $131.7 million.

Core Laboratories Stock Down 4.3 %

Shares of NYSE:CLB opened at $17.75 on Friday. Core Laboratories has a 1 year low of $13.82 and a 1 year high of $25.13. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.48 and a quick ratio of 1.79. The business’s 50-day moving average is $18.94 and its 200-day moving average is $19.48. The company has a market capitalization of $833.36 million, a price-to-earnings ratio of 26.89, a P/E/G ratio of 1.09 and a beta of 2.39.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings results on Wednesday, January 29th. The oil and gas company reported $0.23 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.23. Core Laboratories had a return on equity of 16.43% and a net margin of 5.99%. Equities research analysts predict that Core Laboratories will post 0.96 earnings per share for the current year.

Core Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Monday, February 10th will be issued a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date of this dividend is Monday, February 10th. Core Laboratories’s payout ratio is 6.06%.

Analyst Upgrades and Downgrades

CLB has been the topic of several research reports. StockNews.com upgraded shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Citigroup dropped their price target on Core Laboratories from $15.00 to $14.00 and set a “sell” rating on the stock in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating and three have given a hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.00.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.